The electrophysiology (EP) field has undergone a remarkable transformation over the past decade. Advances in left atrial appendage occlusion (LAAO), atrial fibrillation (AFib) ablation and outpatient ...

YOU ARE HERE: Home > Guidelines and Clinical Policy > 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation ...

The Image and Slide Gallery captures images, videos, or slides which can serve as useful teaching materials in the field of CV medicine.

Among patients with a failed mitral bioprosthetic valve, transcatheter mitral valve-in-valve (mVIV) treatment was associated with a lower rate of death or disabling stroke at one year compared with ...

Learn more about the ACC's committee chairs *This content is reserved for members of the ACC community. Log in to access these resources and more exclusive member perks. YOU ARE HERE: Home > About ACC ...

The U.S. Food and Drug Administration (FDA) has approved the Sapien 3, Sapien 3 Ultra and Sapien 3 Ultra Resilia TAVR valves from Edwards Lifesciences to treat patients with asymptomatic severe aortic ...

Health care professionals should explore the use of glucagon-like peptide-1 receptor agonists (GLP1RAs) for cardiovascular risk reduction and their broader impacts on cardiometabolic health beyond ...

A robust body of observational and Mendelian randomization data establishes a causal relationship between elevated Lp(a) and ASCVD, ischemic stroke and calcific aortic valve stenosis (CAVS). 3 A ...

Chronic consumption of high levels of caffeine a day can lead to an increase in high heart rate and blood pressure that persists after resting from a step test, increasing the risk of cardiovascular ...

Sotatercept, an activin signaling inhibitor, was associated with significant improvements in blood pressure and vascular health in patients with heart failure with preserved ejection fraction (HFpEF) ...

Sleep is a critical physiological process that allows the body to rest, repair and rejuvenate and it has profound implications for systemic health, particularly the cardiovascular system. Along with ...

Spironolactone, an aldosterone blocker, compared with placebo, did not show any significant improvement in terms of heart failure (HF) hospitalizations and cardiovascular death at 24 months in ...